Scarica l'app Stockscreener
1.37
0.00%
0.00
Precedente Chiudi:
$1.37
Aprire:
$1.37
Volume 24 ore:
247.58K
Relative Volume:
0.59
Capitalizzazione di mercato:
$36.50M
Reddito:
$59.07M
Utile/perdita netta:
$-52.66M
Rapporto P/E:
-0.6816
EPS:
-2.01
Flusso di cassa netto:
$-40.16M
1 W Prestazione:
+5.38%
1M Prestazione:
-49.63%
6M Prestazione:
-82.07%
1 anno Prestazione:
-86.41%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$1.275
$1.435
Portata 52W:
$1.255
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Nome
Cvrx Inc
Settore
Industria
Telefono
(763) 416-2850
Indirizzo
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
1.37 | 36.50M | 59.07M | -52.66M | -40.16M | -2.01 |
ABT
Abbott Laboratories
|
102.51 | 177.38B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.59 | 123.55B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.08 | 117.79B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
46.01 | 66.68B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.09 | 51.93B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-07 | Downgrade | Craig Hallum | Buy → Hold |
| 2026-08-07 | Downgrade | Lake Street | Buy → Hold |
| 2026-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-05-09 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-01-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-11 | Reiterato | Lake Street | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2024-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Lake Street | Buy |
| 2022-07-18 | Iniziato | Craig Hallum | Buy |
| 2021-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-26 | Iniziato | Piper Sandler | Overweight |
| 2021-07-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Cvrx Inc Borsa (CVRX) Ultime notizie
Canaccord keeps Buy for CVRx stock as CVRx appoints John Landry CFO - AD HOC NEWS
Form 13D/A CVRx For: 2 October By Investing.com - Investing.com Nigeria
Share sales take a holder below 5% ownership of CVRx (CVRX). - Stock Titan
Why Is CVRx (NASDAQ:CVRX) Suddenly a Must-Watch Smallcap Stocks Name? - Kalkine Media
CVRx Inc. (CVRX) Stock Price | Live Quotes & Charts | NASDAQ - stockstotrade.com
CVRx, Inc. (CVRX) stock price, news, quote and history - Yahoo Finance UK
CVRx, Inc. (CVRX) stock price, news, quote and history - Yahoo Finance Australia
CVRx stock holds steady as investors eye latest revenue growth - AD HOC NEWS
CVRx stock dips as Cantor slashes price target after guidance update - AD HOC NEWS
Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains? - Yahoo Finance
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop - PR Newswire
CVRX stock edges higher as investors watch neuromodulation growth - ad-hoc-news.de
CVRX stock benefits as Barostim heart failure therapy gains new Medicare Advantage coverage - ad-hoc-news.de
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc.CVRX - PR Newswire
CVRx Secures Devoted Health Coverage for Barostim Therapy - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Shareholders to Connect - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims - PR Newswire
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation - accessnewswire.com
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX) - qz.com
CVRx has an activist investor urging it to get acquired - MassDevice
CVRx Responds to Letter from Pointillist Family Office - marketscreener.com
CVRx Responds to Letter from Pointillist Family Office - GlobeNewswire
CVRx responds to shareholder letter on company valuation - Investing.com
CVRx earns new Medicare Advantage coverage policy for Barostim - MassDevice
CVRx Inc. Faces Securities Law Investigation Over Revenue Guidance Cut and DOJ Demand - kalkine.ca
Investor holding 5.5% of CVRx urges board to pursue sale By Investing.com - Investing.com Nigeria
Investor holding 5.5% of CVRx urges board to pursue sale By Investing.com - Investing.com Canada
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy - The Manila Times
Jorey Chernett, Owner of More Than 5.5% of Ou - Moomoo
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy - GlobeNewswire
New CVRx (NASDAQ: CVRX) investor urges board to prioritize a sale - Stock Titan
Jorey Chernett Urges Board to Launch Sale Process - marketscreener.com
Jorey Chernett Pushes for Sale at CVRx with 5.5% Stake - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Investigation launched into CVRx over DOJ probe, sales issues, and sudden CRO firing. - Pluang
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Law firm investigates CVRx for possible securit... - Pluang
Cantor Fitzgerald Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com - Investing.com South Africa
CVRX Q2 2026 Earnings: Modest EPS Beat Offset by 10.71% Share SlidePositive Surprise Momentum - vinanet.vn
Cantor cuts CVRx stock price target on sales execution challenges - Investing.com
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com - Investing.com India
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com - Investing.com Canada
Cvrx Inc Azioni (CVRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cvrx Inc Azioni (CVRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Binkowski Brent | CHIEF OPERATING OFFICER |
Aug 12 '26 |
Sale |
2.55 |
1,309 |
3,338 |
30,291 |
| Adamson Philip B. | Chief Medical Officer |
Mar 02 '26 |
Sale |
7.90 |
1,262 |
9,973 |
61,578 |
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
4.70%
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):